Navigation Links
1st EMEA application filed for product using innovative intradermal microinjection system BD Soluvia
Date:2/13/2008

Franklin Lakes, NJ, USA (February 13, 2008) -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has submitted the first application in Europe to deliver a vaccine using BD Soluvia, the innovative microinjection system developed by BD (Becton, Dickinson and Company). The submission for the first influenza vaccine using BD Soluvia has been accepted for review by the European Medicines Agency (EMEA).

Sanofi Pasteur conducted clinical trials on more than 7000 subjects to evaluate safety and the ability to generate an immune response of the novel intradermal (ID) influenza vaccine. Compared with intramuscular (IM) injection, ID delivery was shown to be especially effective in enhancing the immune response in the elderly1,2. Independently, BD conducted clinical trials involving more than 700 subjects and 3500 injections with BD Soluvia, and demonstrated that the system was safe and easy to use.3. Clinical testing showed that the BD microneedle is barely perceptible when it enters the skin and ensures the administration of the injected solution to the dermal layer irrespective of the subject s gender, age, ethnicity and body mass.4

BD Soluvia is a prefillable microinjection system that is integrated with a tiny BD microneedle. It has been proven to offer a simple, reliable method of delivery. While most vaccines are injected into the muscle, the BD microneedle allows the vaccine to be accurately delivered intradermally -- within the dermal layer of the skin. The dermal layer contains a dense network of lymphatic vessels feeding local lymph nodes, resulting in rapid and efficient access of the vaccine into the immune system. It also contains a high concentration of potent immune cells that play a key role to initiate the immune response following vaccination.

BD is committed to developing innovative solutions to advance drug delivery with pharmaceutical companies, and to meet the needs of healthcare professionals, said Philippe Laurent, Vice President, Medical Affairs, BD Medical V Pharmaceutical Systems. The BD Soluvia microinjection system is a breakthrough technology that is intuitive to use and allows accurate and consistent delivery of substances such as the flu vaccine into the dermal layer. We believe it has the potential to help address some of the important health challenges facing the world today, and embodies BD s purpose of helping all people live healthy lives.

We are delighted to have reached this landmark in development with our partner, sanofi pasteur, said Alex Conroy, President, BD Medical - Pharmaceutical Systems. In practical terms, the BD Soluvia microinjection system has the potential to increase patients acceptance of injections and enhance immunization practices. BD is deeply committed to continuing the development of BD Soluvia for the intradermal route of administration for use with infectious disease and emerging cancer vaccines.


'/>"/>
Contact: Alyssa Zeff
Alyssa_Zeff@bd.com
201-847-4358
Ruder Finn Public Relations
Source:Eurekalert

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Investigational New Drug Application for Fat Melting Injections Cleared by the FDA
3. PreMD Provides Update on 510(k) Application for PREVU(x) POC
4. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
5. Medical Services International Inc. Completes Testing for European Union (EU) Application
6. Pharsight Files Application for Nasdaq Capital Market Listing
7. PartsSource Awarded US Patent for PartsFinder(TM) Application
8. HealthCentral.com Launches Greeting Card Application on Facebook.com
9. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. FDA Accepts New Drug Application for Priority Review of Investigational HIV Treatment TMC125
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... Christmas:” a beautiful and enchanting tale that teaches children the true meaning of Christmas. “Journey ... Oklahoma City, and a devoted woman of faith. , “Becoming a parent changes you. ... of my mind for years, but actually doing it might have been a while in ...
(Date:1/19/2017)... ... ... the Centers for Medicare & Medicaid Services (CMS) announced over 359,000 clinicians are ... who participate in APMs are paid for the quality of care they give to ... a system that delivers better care and one in which clinicians work together to ...
(Date:1/19/2017)... ... 2017 , ... With the cold weather here, many people will have to clear snow with ... large amounts of snow, but they can be dangerous when used incorrectly. That’s why ... for the proper use of snow blowers:, , When removing wet ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable Teleultrasound ... an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images and ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... certified dermatologist by the American Board of Dermatology and fellowship trained Mohs and ... the National Institutes of Health, Dr. Li completed his internship in internal medicine ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
(Date:1/19/2017)... -- Conference Call and Webcast to Follow Vanda Pharmaceuticals ... release results for the fourth quarter of 2016 on Wednesday, February ... ... 4:30 PM ET on Wednesday, February 15, 2017, during which management ... and other corporate activities. To participate in the conference call, please ...
Breaking Medicine Technology: